<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248701</url>
  </required_header>
  <id_info>
    <org_study_id>B1449-R</org_study_id>
    <secondary_id>1I01RX001449-01A1</secondary_id>
    <secondary_id>1IK1RX002327-01A1</secondary_id>
    <nct_id>NCT02248701</nct_id>
  </id_info>
  <brief_title>Testosterone Plus Finasteride Treatment After Spinal Cord Injury</brief_title>
  <official_title>Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether testosterone plus finasteride treatment
      will improve musculoskeletal health, neuromuscular function, body composition, and metabolic
      health in hypogonadal men who have experienced ambulatory dysfunction subsequent to
      incomplete spinal cord injury. The investigators hypothesize that this treatment will improve
      bone mineral density, enhance muscle size and muscle function, and improve body composition,
      without causing prostate enlargement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men with spinal cord injury (SCI) experience a high prevalence of hypogonadism which
      influences the neural, muscular, skeletal, and body composition deficits that occur after
      injury. It remains unknown whether testosterone administration improves bone mineral density,
      muscle mass and muscle function, and body composition / metabolic health in hypogonadal men
      who have experienced ambulatory dysfunction subsequent to incomplete spinal cord injury. In
      addition, it is unknown whether testosterone or the 5-alpha reduced metabolite
      dihydrotestosterone (an endogenous metabolite of testosterone) mediate effects in these and
      other tissues.

      For this study hypogonadal men with motor incomplete spinal cord injury who present with
      ambulatory dysfunction will be randomized to receive testosterone plus the 5-alpha reductase
      inhibitor finasteride or a placebo treatment for 12 months. Testosterone or placebo injection
      will be administered weekly; finasteride or placebo will be administered daily. Participants
      will be assessed at study entry and at 1-6 month intervals thereafter. Assessments will
      include measurements such as a dual energy x-ray absorptiometry (DEXA) scan, MRI scan, and
      muscle performance tests. Participants will also have several safety tests, including
      electrocardiogram (EKG) for cardiac electrophysiology, prostate digital rectal exam and
      prostate ultrasound sizing for prostate health, and blood tests to assess hematocrit, liver
      enzymes (AST and ALT), prostate specific antigen (PSA), cholesterol, and other health
      markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hip Bone Mineral Density</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in hip bone mineral density assessed via dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Muscle Cross-Sectional Area</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in thigh muscle cross-sectional area assessed via MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Body Fat</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in total body fat assessed via DXA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Walking Speed</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in 10 m walking speed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Neuromuscular Function</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in thigh muscle force production assessed via dynamometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visceral Fat</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in visceral fat mass assessed via DXA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Spinal Cord Injuries</condition>
  <condition>Trauma, Nervous System</condition>
  <condition>Wounds and Injuries</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Spinal Cord Diseases</condition>
  <condition>Gonadal Disorders</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Hypogonadism</condition>
  <condition>Genital Diseases, Male</condition>
  <arm_group>
    <arm_group_label>testosterone enanthate, finasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo via i.m. injection (once weekly) and placebo pill orally (daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone enanthate, finasteride</intervention_name>
    <description>Subjects receive testosterone (125 mg/week) by intramuscular injection and finasteride (5 mg/day) orally</description>
    <arm_group_label>testosterone enanthate, finasteride</arm_group_label>
    <other_name>delatestryl, proscar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects receive weekly placebo injection and placebo pill daily</description>
    <arm_group_label>placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male &gt; 18 years of age

          -  Traumatic, vascular, or orthopedic spinal cord injury between C2-L3 &gt;12 months prior
             to enrollment

          -  Motor incomplete spinal cord (AIS C/D)

          -  Ambulatory dysfunction

          -  Medically stable condition that is asymptomatic for bladder infection, decubiti,
             cardiopulmonary disease, or other significant medical conditions

          -  Serum total testosterone (&lt;325 ng/dL) or bioavailable testosterone (&lt;70 ng/dL)

        Exclusion Criteria:

          -  Currently participating in another research protocol that may influence study outcomes

          -  Life expectancy &lt;1 year

          -  History of or current congenital spinal cord injury or other degenerative spinal
             disorder

          -  Diagnosis of multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic
             impairment/injury

          -  History of venous thromboembolism within the last 6 months, specifically deep venous
             thromboembolism and pulmonary embolism, history of recurrent venous thromboembolism or
             know hereditary thrombophilia

          -  Poorly compensated or uncontrolled cardiovascular disease

          -  Any major cardiovascular event within the last 6 months (defined as a history of acute
             myocardial infarction, any cardiac revascularization procedure including angioplasty,
             stenting, or coronary artery bypass grafting, hospitalization due to unstable angina,
             transient ischemic attack, or stroke)

          -  Any angina that is not controlled on a current medical regimen (Canadian class II,
             III, or IV)

          -  New York Heart Association (NYHA) class III or IV congestive heart failure

          -  Systolic blood pressure 160 mmHg or diastolic blood pressure 100 mm Hg

          -  Poorly controlled arrhythmia

          -  Severe valvular disease

          -  LDL cholesterol &gt;160 mg/dl with known history of any major cardiovascular event, as
             defined above, within the last 6 months

          -  Baseline EKG findings (e.g. left bundle branch block) or marked EKG abnormalities that
             would preclude serial screening for occult ischemic events

          -  History of or current prostate, breast, or other organ cancer

          -  Serum prostate-specific antigen (PSA) &gt;3.0 ng/ml

          -  History of benign prostate enlargement (BPE) &gt;40cc, evaluated via TRUS

          -  Hematocrit &gt;47%

          -  Liver enzymes (AST / ALT) above normal upper limit

          -  Creatinine &gt;1.4 mg/dL

          -  Serum calcium &gt;10.5 mg/dL

          -  Gynecomastia

          -  Mental state that precludes understanding of the protocol

          -  Diagnosed, but untreated moderate or severe sleep apnea

          -  Spinal nutrition screening tool score &gt; 15

          -  Severe claustrophobia that precludes MRI testing

          -  Current anticoagulant therapy

          -  Use of any of the following pharmacologic agents in the previous 3 months
             (testosterone, leuprolide, androgenic hormones, growth hormone, oral androgen
             precursors, 5-alpha reductase or aromatase inhibitors)

          -  Use of anti-resorptive or bone anabolic drug therapy in the previous 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must be male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua F Yarrow, PhD MS BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Florida/South Georgia Veterans Health System, Gainesville, FL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua F Yarrow, PhD MS BS</last_name>
    <phone>(352) 376-1611</phone>
    <phone_ext>6477</phone_ext>
    <email>joshua.yarrow@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana M Otzel, PhD</last_name>
    <phone>(352) 376-1611</phone>
    <phone_ext>6917</phone_ext>
    <email>Dana.Otzel@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System, Gainesville, FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua F Yarrow, PhD MS BS</last_name>
      <phone>352-376-1611</phone>
      <phone_ext>6477</phone_ext>
      <email>joshua.yarrow@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Dana M Otzel, PhD</last_name>
      <phone>(352) 376-1611</phone>
      <phone_ext>6917</phone_ext>
      <email>Dana.Otzel@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua F Yarrow, PhD MS BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans' Hospital, Tampa, FL</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua F Yarrow, PhD</last_name>
      <phone>352-376-1611</phone>
      <phone_ext>6477</phone_ext>
      <email>Joshua.Yarrow@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Dana M Otzel, PhD</last_name>
      <phone>3523761611</phone>
      <phone_ext>6917</phone_ext>
      <email>Dana.Otzel@va.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Testosterone enanthate</keyword>
  <keyword>Testosterone undecanoate</keyword>
  <keyword>Testosterone 17 beta-cypionate</keyword>
  <keyword>Methyltestosterone</keyword>
  <keyword>Androgens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormone Substitutes, and Hormone Antagonists</keyword>
  <keyword>Physiologic Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Antineoplastic Agents, Hormonal</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Anabolic Agents</keyword>
  <keyword>Testosterone Replacement Therapy</keyword>
  <keyword>Dual Energy X ray Absorptiometry</keyword>
  <keyword>Lean Tissue Mass</keyword>
  <keyword>Body Composition</keyword>
  <keyword>Lipid and Glucose profile</keyword>
  <keyword>Muscle Strength</keyword>
  <keyword>5-alpha Reductase</keyword>
  <keyword>Muscle Mass</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Adipose Tissue</keyword>
  <keyword>Body Fat</keyword>
  <keyword>Density, Bone</keyword>
  <keyword>Bone Formation</keyword>
  <keyword>Bone Resorption</keyword>
  <keyword>Bone Density Conservation Agents</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Muscle, Skeletal</keyword>
  <keyword>Bone and Bones</keyword>
  <keyword>Gait</keyword>
  <keyword>Walking</keyword>
  <keyword>Locomotion</keyword>
  <keyword>Motor Activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Genital Diseases, Male</mesh_term>
    <mesh_term>Trauma, Nervous System</mesh_term>
    <mesh_term>Gonadal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Finasteride</mesh_term>
    <mesh_term>Antineoplastic Agents, Hormonal</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Bone Density Conservation Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

